drugset / Trial / NCT00266565

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

NCT00266565

Phase 1/2 Completed 24 enrolled Children's Hospital Medical Center, Cincinnati
NaSingle-groupOpen-labelTreatment

Summary

Toxicity of anti-IL-5

Timeline

Start
2001-12
Primary completion
2005-04
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Mepolizumab Monoclonal antibody 10 mg/kg Intravenous